First Eagle Investment Management’s Corcept Therapeutics CORT Stock Holding History

First Eagle Investment Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-125,000	Closed	-$813K	–	338
2016 Q3	$813K	Sell	125,000 -98,935	-44%	-$575K	﹤0.01%	245
2016 Q2	$1.22M	Sell	223,935 -171,735	-43%	-$893K	﹤0.01%	242
2016 Q1	$1.85M	Buy	395,670 +95,670	+32%	+$373K	﹤0.01%	212
2015 Q4	$1.49M	Hold	300,000	–	–	﹤0.01%	209
2015 Q3	$1.13M	Buy	300,000 +100,000	+50%	+$507K	﹤0.01%	217
2015 Q2	$1.2M	Buy	+200,000	New	+$1.23M	﹤0.01%	215
2014 Q1	–	Sell	-991,978	Closed	-$3.19M	–	392
2013 Q4	$3.19M	Sell	991,978 -1,504,100	-60%	-$3.04M	0.01%	178
2013 Q3	$3.97M	Sell	2,496,078 -40,788	-2%	-$71.9K	0.01%	185
2013 Q2	$4.39M	Buy	+2,536,866	New	+$4.56M	0.01%	194

Other funds holding CORT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Eagle Investment Management's CORT Position: Q4 2016 in Review

First Eagle Investment Management sold out of Corcept Therapeutics (CORT) in Q4 2016, closing a stake of 125,000 shares — an estimated $813K sold.

First Eagle Investment Management first reported a position in CORT in Q2 2013 and held it in 9 quarters. The position peaked at $4.39M in Q2 2013. 135 funds tracked by Wall St. Rank hold CORT as of Q4 2016.

First Eagle Investment Management reported no remaining Corcept Therapeutics position as of Q4 2016 after selling out during the quarter.
First Eagle Investment Management sold 125,000 Corcept Therapeutics shares in Q4 2016, an estimated $813K.
First Eagle Investment Management first reported a position in Corcept Therapeutics in Q2 2013 and held it in 9 quarters.
First Eagle Investment Management's Corcept Therapeutics position peaked at $4.39M in Q2 2013.
135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2016.

Based on First Eagle Investment Management's 13F filing for Q4 2016, filed 6 Feb 2017.